sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Condition:   Gastro-Intestinal Cancer
Intervention:   Drug: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Sponsor:   Rutgers, The State University of New Jersey

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 28, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine